BRAF and melanoma: The overall findings of the study indicate that PTENP1-AS could be an effective target for re-sensitizing melanoma cells to BRAF inhibitor therapy and may also serve as a potential prognostic marker for clinical outcomes in patients with stage III melanoma.84